Skip to main content
BBIO
NASDAQ Life Sciences

FDA Grants Priority Review to BridgeBio's Oral Infigratinib for Achondroplasia

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$65.75
Mkt Cap
$12.854B
52W Low
$52.75
52W High
$93.415
52W Position info
25% above low
Off High info
30% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BBIO sits 25% above its 52-week low of $52.75.

Summary

BridgeBio's NDA for oral infigratinib in children with achondroplasia was accepted by the FDA with Priority Review and a PDUFA date of February 4, 2027. The filing is supported by Phase 3 data showing the strongest efficacy package reported to date in achondroplasia.


Key Events · Product Development and Regulatory · BBIO

  • FDA Accepts NDA with Priority Review

    FDA accepted BridgeBio's NDA for oral infigratinib in children with achondroplasia and granted Priority Review, with a PDUFA target action date of February 4, 2027.

  • Strongest Phase 3 Efficacy Data in Achondroplasia

    PROPEL 3 met its primary endpoint with a mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001) and showed the first statistically significant improvements in body proportionality and arm span in an achondroplasia Phase 3 trial.

  • First-in-Class Oral Therapy Potential

    If approved, oral infigratinib would be the first and only approved oral therapy for children with achondroplasia, with BridgeBio anticipating U.S. launch upon approval.

  • Regulatory Timeline

    PDUFA target action date is February 4, 2027. BridgeBio also plans to submit a Marketing Authorization Application to the EMA in Q4 2026.


Analysis · BBIO · Life Sciences

The FDA accepted BridgeBio's NDA for oral infigratinib in children with achondroplasia and granted Priority Review, setting a PDUFA date of February 4, 2027. This is a major regulatory milestone for a potential first-in-class oral therapy. The PROPEL 3 data supporting the filing showed the largest annualized height velocity treatment effect of any Phase 3 study in achondroplasia (+2.10 cm/yr; p<0.0001) and the first statistically significant improvements in body proportionality and arm span. If approved, infigratinib would be the first and only oral therapy for this indication, positioning BridgeBio for a U.S. launch upon approval. The Priority Review designation reflects the FDA's recognition of significant unmet need, and the February 2027 PDUFA date gives investors a concrete near-term catalyst.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $65.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $52.75 to $93.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $79.55 info
Change: +$8.86 (+13%) info
Market Cap: $15.494B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $79.55 info
Change: +$8.11 (+11%) info
Market Cap: $15.494B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $79.55 info
Change: +$8.88 (+13%) info
Market Cap: $15.494B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $79.55 info
Change: +$14.20 (+22%) info
Market Cap: $15.494B info
BBIO
Oct 11, 2026, 11:42 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $79.55 info
Change: +$14.20 (+22%) info
Market Cap: $15.494B info